ABCAM Plc Application for admission to trading (3978F)
November 11 2015 - 10:17AM
UK Regulatory
TIDMABC
RNS Number : 3978F
ABCAM Plc
11 November 2015
For immediate release 11 November 2015
ABCAM PLC
("Abcam" or "the Company")
Application for admission to trading
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the
supply of life science research tools, announces that pursuant to
the agreement to acquire the entire issued share capital of AxioMx,
Inc. announced earlier today, an application has been made to AIM
for the admission to trading of 881,030 new ordinary shares of 0.2p
each in the Company in connection with the Acquisition. The new
ordinary shares will rank pari passu in all respects with the
existing shares in issue (including the final dividend, the record
date in respect of which is 13 November 2015). The new ordinary
shares are subject to an orderly market agreement.
As a consequence of the issue of the new ordinary shares in
connection with the Acquisition the Company's issued ordinary share
capital comprises 202,208,530 ordinary shares of 0.2p each with
voting rights. This figure may be used by shareholders as a
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, Abcam under the FCA's Disclosure and Transparency
Rules.
For further information please contact:
+ 44 (0) 1223
Abcam 696 000
Suzanne Smith, Company Secretary
J.P.Morgan Cazenove - Nominated Adviser & Corporate + 44 (0) 20 7742
Broker 4000
James Mitford / Alex Bruce - Nominated Adviser
Notes to Editors
About Abcam
Abcam plc is a global leader in the supply of life science
research tools, with a wide range of products and expert technical
support, enabling scientists to analyse living cells at the
molecular level and improving the understanding of health and
disease.
Abcam is committed to providing scientists with an extensive
choice of reagents and tools, with the most comprehensive, honest
and up-to-date datasheets and customer reviews, fast delivery and
helpful customer service & technical support. The Company's
catalogue evolves with scientific research trends and is growing
each year to provide customers with products to meet their research
needs. The range now includes primary and secondary antibodies,
proteins, peptides, lysates, biochemicals, immunoassays and other
kits. Abcam also supports its customers by hosting a range of
global scientific events, forums and webinars, providing
opportunities for scientists to get together and present their
work.
Headquartered in Cambridge, UK, Abcam has nine global subsidiary
offices enabling local services and multi-language support and
sells to over 130 countries. The Company was founded in 1998, and
now employs over 820 people. Abcam was admitted to AIM in 2005
(AIM: ABC).
To find out more, please visit www.abcam.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
LISEFLFFEFFFFBE
(END) Dow Jones Newswires
November 11, 2015 10:17 ET (15:17 GMT)
Abcam (LSE:ABC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abcam (LSE:ABC)
Historical Stock Chart
From Apr 2023 to Apr 2024